Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PACB Stock Forecast 2025-2026
$1.31
Current Price
$390.11M
Market Cap
Buy 6
Hold 7
Sell 0
Wall St Analyst Ratings
Distance to PACB Price Targets
+129.0%
To High Target of $3.00
+52.7%
To Median Target of $2.00
-4.6%
To Low Target of $1.25
PACB Price Momentum
+11.0%
1 Week Change
+28.4%
1 Month Change
-20.6%
1 Year Change
-28.4%
Year-to-Date Change
-51.8%
From 52W High of $2.72
+54.1%
From 52W Low of $0.85
📊 TOP ANALYST CALLS
Did PACB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Pacific Biosciences is one of their latest high-conviction picks.
Latest PACB Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, PACB has a neutral consensus with a median price target of $2.00 (ranging from $1.25 to $3.00). The overall analyst rating is Buy (7.7/10). Currently trading at $1.31, the median forecast implies a 52.7% upside. This outlook is supported by 6 Buy, 7 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kyle Mikson at Canaccord Genuity, projecting a 129.0% upside. Conversely, the most conservative target is provided by David Westenberg at Piper Sandler, suggesting a 4.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PACB Analyst Ratings
6
Buy
7
Hold
0
Sell
PACB Price Target Range
Low
$1.25
Average
$2.00
High
$3.00
Current: $1.31
Latest PACB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PACB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 15, 2025 | Piper Sandler | David Westenberg | Neutral | Maintains | $1.25 |
| May 15, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $1.80 |
| Apr 10, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $3.00 |
| Mar 25, 2025 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $2.00 |
| Feb 20, 2025 | Piper Sandler | David Westenberg | Neutral | Reiterates | $2.00 |
| Feb 18, 2025 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $1.50 |
| Feb 18, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $2.50 |
| Feb 14, 2025 | Stephens & Co. | Mason Carrico | Overweight | Reiterates | $2.50 |
| Jan 23, 2025 | Goldman Sachs | Matthew Sykes | Neutral | Maintains | $1.75 |
| Nov 11, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $6.00 |
| Nov 11, 2024 | Piper Sandler | David Westenberg | Neutral | Maintains | $2.50 |
| Nov 11, 2024 | UBS | John Sourbeer | Neutral | Downgrade | $2.00 |
| Aug 28, 2024 | Scotiabank | Sung Ji Nam | Sector Outperform | Maintains | $7.00 |
| Aug 13, 2024 | Stephens & Co. | Overweight | Maintains | $0.00 | |
| Aug 12, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $2.00 |
| Aug 8, 2024 | Cantor Fitzgerald | Ross Osborn | Overweight | Reiterates | $3.50 |
| Aug 8, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $3.00 |
| Jun 3, 2024 | Jefferies | Tycho Peterson | Buy | Initiates | $4.00 |
| May 15, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $4.00 |
| May 13, 2024 | Piper Sandler | David Westenberg | Neutral | Maintains | $2.00 |
Pacific Biosciences of California, Inc. (PACB) Competitors
The following stocks are similar to Pacific Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Pacific Biosciences of California, Inc. (PACB) Financial Data
Pacific Biosciences of California, Inc. has a market capitalization of $390.11M with a P/E ratio of -1.2x. The company generates $152.36M in trailing twelve-month revenue with a 24.2% profit margin.
Revenue growth is -4.3% quarter-over-quarter, while maintaining an operating margin of -1,164.5% and return on equity of -177.6%.
Valuation Metrics
Market Cap
$390.11M
Enterprise Value
$749.11M
P/E Ratio
-1.2x
PEG Ratio
-1.9x
Price/Sales
2.6x
Growth & Margins
Revenue Growth (YoY)
-4.3%
Gross Margin
-3.7%
Operating Margin
-1,164.5%
Net Margin
+24.2%
EPS Growth
-4.3%
Financial Health
Cash/Price Ratio
+87.3%
Current Ratio
6.7x
Debt/Equity
766.2x
ROE
-177.6%
ROA
-31.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Pacific Biosciences of California, Inc. (PACB) Business Model
About Pacific Biosciences of California, Inc.
What They Do
Develops innovative sequencing systems for biotechnology.
Business Model
The company operates by creating advanced sequencing platforms, particularly its flagship SMRT technology, which facilitates detailed genetic analysis for researchers across various fields. By selling these systems and providing associated services, it generates revenue while supporting advancements in genomics, personalized medicine, and other scientific areas.
Additional Information
Pacific Biosciences is strategically positioned in the growing biotechnology market, focusing on high-fidelity and long-read sequencing capabilities. Its technology is crucial for enhancing the understanding of complex genetic information, which is essential for developing targeted therapies and diagnostics in healthcare, agriculture, and environmental biology.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
575
CEO
Mr. Christian O. Henry M.B.A.
Country
United States
IPO Year
2010
Website
www.pacb.comPacific Biosciences of California, Inc. (PACB) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Why Is Steris (STE) Down 1.8% Since Last Earnings Report?
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Jun 13, 2025
By Zacks Equity Research
Realtime BLOG
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know
Pacific Biosciences of California (PACB) closed at $1.18 in the latest trading session, marking a +1.72% move from the prior day.
Jun 12, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Pacific Biosciences of California (PACB) Outperforms Broader Market: What You Need to Know
7 days ago
Quick Summary
Pacific Biosciences of California (PACB) closed at $1.18, up 1.72% from the previous trading day.
Why It Matters
PACB's slight increase in stock price indicates potential positive market sentiment or investor confidence, which may influence future trading decisions and valuations.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
PACB reports strong Q1 results, leveraging product innovation and cost reductions to counteract sales cycle delays, positioning for growth in 2025.
Why It Matters
PACB's strong Q1 results and strategic innovations signal potential for future growth, which may enhance investor confidence and influence stock performance.
Source: Zacks Investment Research
Market Sentiment:
Positive
Target ALS Chooses PacBio HiFi Sequencing to Advance ALS Research with Largest Global Genomic Study to Date
17 days ago
Quick Summary
Target ALS and PacBio have launched a global initiative to sequence 6,000 genomes for ALS research, providing free access to detailed long-read sequencing data for scientists worldwide.
Why It Matters
The partnership between Target ALS and PacBio signals potential advancements in ALS research, possibly leading to breakthroughs that could drive biotech investments and innovations in treatments.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Pacific Biosciences (PACB) has received a Zacks Rank #2 (Buy), indicating growing optimism about its earnings prospects, which may lead to a potential increase in its stock price.
Why It Matters
Growing optimism and a Zacks Rank #2 (Buy) suggest improved earnings potential for Pacific Biosciences, indicating a potentially favorable investment opportunity.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
PACB partners with Haorui Gene to expand HiFi sequencing services in China, enhancing access to precision medicine across clinical labs nationwide.
Why It Matters
PACB's partnership in China enhances its market presence, potentially increasing revenue from precision medicine and driving demand for its HiFi sequencing technology, positively impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Neutral
Quick Summary
PacBio's Board Special Committee has completed an investigation into employment practices and cybersecurity allegations, finding no improper practices or inaccuracies in its 2024 Form 10-K.
Why It Matters
The conclusion of the investigation clears PacBio of allegations, potentially stabilizing investor confidence and reducing uncertainty around the company's governance and cybersecurity practices.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PACB Stock
What is Pacific Biosciences of California, Inc.'s (PACB) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Pacific Biosciences of California, Inc. (PACB) has a median price target of $2.00. The highest price target is $3.00 and the lowest is $1.25.
Is PACB stock a good investment in 2025?
According to current analyst ratings, PACB has 6 Buy ratings, 7 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.31. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PACB stock?
Wall Street analysts predict PACB stock could reach $2.00 in the next 12 months. This represents a 52.7% increase from the current price of $1.31. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Pacific Biosciences of California, Inc.'s business model?
The company operates by creating advanced sequencing platforms, particularly its flagship SMRT technology, which facilitates detailed genetic analysis for researchers across various fields. By selling these systems and providing associated services, it generates revenue while supporting advancements in genomics, personalized medicine, and other scientific areas.
What is the highest forecasted price for PACB Pacific Biosciences of California, Inc.?
The highest price target for PACB is $3.00 from Kyle Mikson at Canaccord Genuity, which represents a 129.0% increase from the current price of $1.31.
What is the lowest forecasted price for PACB Pacific Biosciences of California, Inc.?
The lowest price target for PACB is $1.25 from David Westenberg at Piper Sandler, which represents a -4.6% decrease from the current price of $1.31.
What is the overall PACB consensus from analysts for Pacific Biosciences of California, Inc.?
The overall analyst consensus for PACB is neutral. Out of 18 Wall Street analysts, 6 rate it as Buy, 7 as Hold, and 0 as Sell, with a median price target of $2.00.
How accurate are PACB stock price projections?
Stock price projections, including those for Pacific Biosciences of California, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 19, 2025 9:26 AM UTC